Literature DB >> 15138594

Perfusion, oxygenation status and growth of experimental tumors upon photodynamic therapy with Pd-bacteriopheophorbide.

Debra K Kelleher1, Oliver Thews, Avigdor Scherz, Yoram Salomon, Peter Vaupel.   

Abstract

The aim of this study was to assess the anti-tumor effect of photodynamic therapy (PDT) using a novel bacteriochlorophyll derivative, palladium-bacteriopheophorbide (TOOKAD) on tumor growth, perfusion and oxygenation. Rat DS-sarcomas were treated with either TOOKAD-PDT (2 mg/kg, i.v., immediate illumination) or one of the control treatments (sham-treatment, illumination without photosensitizer, or photosensitizer without illumination). The light source was an infrared-A irradiator fitted with appropriate filters, so that the wavelengths applied (665-800 nm) included the absorption maximum of TOOKAD at 763 nm. Tumor volume was monitored for 90 days after treatment or until a target volume (3.5 ml) was reached. TOOKAD-PDT dramatically inhibited tumor growth with 92% of tumors not reaching the target volume within the observation period. In further experiments, tumor perfusion was assessed using laser Doppler flowmetry. Upon TOOKAD-PDT treatment, a rapid, pronounced decrease in perfusion was seen, down to levels corresponding to only 3% of initial values. Tumor oxygenation monitoring revealed parallel decreases, with levels corresponding to anoxia being reached. The significant anti-tumor effects presented in this report, taken together with the chemical and pharmacokinetic properties of the novel photosensitizer TOOKAD, underline the therapeutic potential of this approach in which flow stasis and induction of anoxia are key elements.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15138594

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  4 in total

1.  Neuropilin-1 targeting photosensitization-induced early stages of thrombosis via tissue factor release.

Authors:  Denise Bechet; Loraine Tirand; Béatrice Faivre; François Plénat; Corinne Bonnet; Thierry Bastogne; Céline Frochot; François Guillemin; Muriel Barberi-Heyob
Journal:  Pharm Res       Date:  2010-01-20       Impact factor: 4.200

2.  Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure.

Authors:  Abdel-Rahmene Azzouzi; Souhil Lebdai; Fawzi Benzaghou; Christian Stief
Journal:  World J Urol       Date:  2015-03-19       Impact factor: 4.226

3.  Focal treatment of prostate cancer with vascular-targeted photodynamic therapy.

Authors:  Scott E Eggener; Jonathan A Coleman
Journal:  ScientificWorldJournal       Date:  2008-10-03

Review 4.  Photosensitizers in prostate cancer therapy.

Authors:  Taher Gheewala; Troy Skwor; Gnanasekar Munirathinam
Journal:  Oncotarget       Date:  2017-05-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.